Sutro Biopharma (STRO) Cash & Equivalents (2016 - 2026)

Sutro Biopharma has reported Cash & Equivalents for 10 years, with the latest figure at $58.1 million in Q4 2025.

• Quarterly Cash & Equivalents fell 69.45% year-over-year to $58.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.1 million (down 69.45% YoY) and the FY2025 annual result came in at $58.1 million, down 69.45% from the prior year.
• Cash & Equivalents slipped to $58.1 million in Q4 2025 per STRO's latest filing, from $65.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $235.1 million in Q2 2023 and troughed at $28.9 million in Q1 2022.
• A 5-year average of $84.5 million and a median of $65.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents plunged 85.25% in 2021, then soared 215.17% in 2022.
• Over 5 years, Cash & Equivalents stood at $30.4 million in 2021, then soared by 55.37% to $47.3 million in 2022, then soared by 46.59% to $69.3 million in 2023, then jumped by 174.74% to $190.3 million in 2024, then slumped by 69.45% to $58.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $58.1 million, $65.9 million, and $64.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.